Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Structure-Activity Relationships of Wollamide Cyclic Hexapeptides with Activity against Drug-Resistant and Intracellular Mycobacterium tuberculosis.

Khalil ZG, Hill TA, De Leon Rodriguez LM, Lohman RJ, Hoang HN, Reiling N, Hillemann D, Brimble MA, Fairlie DP, Blumenthal A, Capon RJ.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01773-18. doi: 10.1128/AAC.01773-18. Print 2019 Mar.

2.

Validation of the FluoroType® MTBDR assay using respiratory and lymph node samples.

Haasis C, Rupp J, Andres S, Schlüter B, Kernbach M, Hillemann D, Kranzer K.

Tuberculosis (Edinb). 2018 Dec;113:76-80. doi: 10.1016/j.tube.2018.09.004. Epub 2018 Sep 19.

PMID:
30514516
3.

A Diagnostic Algorithm To Investigate Pyrazinamide and Ethambutol Resistance in Rifampin-Resistant Mycobacterium tuberculosis Isolates in a Low-Incidence Setting.

Andres S, Gröschel MI, Hillemann D, Merker M, Niemann S, Kranzer K.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01798-18. doi: 10.1128/AAC.01798-18. Print 2019 Feb.

4.

Sporotrichoid fish tank granuloma.

Koushk-Jalali B, Freitag AP, Tigges C, Oellig F, Hillemann D, Kreuter A.

QJM. 2019 Feb 1;112(2):147. doi: 10.1093/qjmed/hcy203. No abstract available.

PMID:
30239964
5.

Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".

Köser CU, Heyckendorf J, Andres S, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00616-18. doi: 10.1128/AAC.00616-18. Print 2018 Aug. No abstract available.

6.

Smear Microscopy for Diagnosis of Pulmonary Tuberculosis in Eastern Sudan.

Shuaib YA, Khalil EAG, Schaible UE, Wieler LH, Bakheit MAM, Mohamed-Noor SE, Abdalla MA, Homolka S, Andres S, Hillemann D, Lonnroth K, Richter E, Niemann S, Kranzer K.

Tuberc Res Treat. 2018 Jun 14;2018:8038137. doi: 10.1155/2018/8038137. eCollection 2018.

7.

Evaluation of OMNIgene®•SPUTUM reagent for mycobacterial culture.

Zallet J, Olaru ID, Witt AK, Vock P, Kalsdorf B, Andres S, Hillemann D, Kranzer K.

Int J Tuberc Lung Dis. 2018 Aug 1;22(8):945-949. doi: 10.5588/ijtld.17.0020.

8.

Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex.

Maurer FP, Pohle P, Kernbach M, Sievert D, Hillemann D, Rupp J, Hombach M, Kranzer K.

Clin Microbiol Infect. 2019 Mar;25(3):379.e1-379.e7. doi: 10.1016/j.cmi.2018.06.010. Epub 2018 Jun 12.

PMID:
29906595
9.

Validation of the FluoroType MTBDR Assay for Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Complex Isolates.

Hillemann D, Haasis C, Andres S, Behn T, Kranzer K.

J Clin Microbiol. 2018 May 25;56(6). pii: e00072-18. doi: 10.1128/JCM.00072-18. Print 2018 Jun.

10.

Performance of the TB-LAMP diagnostic assay in reference laboratories: Results from a multicentre study.

Pham TH, Peter J, Mello FCQ, Parraga T, Lan NTN, Nabeta P, Valli E, Caceres T, Dheda K, Dorman SE, Hillemann D, Gray CM, Perkins MD.

Int J Infect Dis. 2018 Mar;68:44-49. doi: 10.1016/j.ijid.2018.01.005. Epub 2018 Feb 2.

11.

First Time Isolation of Mycobacterium hassiacum From a Respiratory Sample.

Deinhardt-Emmer S, Höring S, Mura C, Hillemann D, Hermann B, Sachse S, Bohnert J, Löffler B.

Clin Med Insights Circ Respir Pulm Med. 2018 Jan 3;12:1179548417747529. doi: 10.1177/1179548417747529. eCollection 2018.

12.

What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.

Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb.

13.

[Consensus-Based Guidelines for Diagnosis, Prevention and Treatment of Tuberculosis in Children and Adolescents - A Guideline on Behalf of the German Society for Pediatric Infectious Diseases (DGPI)].

Feiterna-Sperling C, Brinkmann F, Adamczick C, Ahrens F, Barker M, Berger C, Berthold LD, Bogyi M, von Both U, Frischer T, Haas W, Hartmann P, Hillemann D, Hirsch FW, Kranzer K, Kunitz F, Maritz E, Pizzulli A, Ritz N, Schlags R, Spindler T, Thee S, Weizsäcker K.

Pneumologie. 2017 Oct;71(10):629-680. doi: 10.1055/s-0043-116545. Epub 2017 Oct 10. German.

PMID:
29017219
14.

Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study.

van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM, Katarzyna Szafrańska A, Hillemann D, Chand M, Schreiber PW, Sommerstein R, Berger C, Genoni M, Rüegg C, Troillet N, Widmer AF, Becker SL, Herrmann M, Eckmanns T, Haller S, Höller C, Debast SB, Wolfhagen MJ, Hopman J, Kluytmans J, Langelaar M, Notermans DW, Ten Oever J, van den Barselaar P, Vonk ABA, Vos MC, Ahmed N, Brown T, Crook D, Lamagni T, Phin N, Smith EG, Zambon M, Serr A, Götting T, Ebner W, Thürmer A, Utpatel C, Spröer C, Bunk B, Nübel U, Bloemberg GV, Böttger EC, Niemann S, Wagner D, Sax H.

Lancet Infect Dis. 2017 Oct;17(10):1033-1041. doi: 10.1016/S1473-3099(17)30324-9. Epub 2017 Jul 12.

PMID:
28711585
15.

How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?

Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):721-726. doi: 10.5588/ijtld.17.0140.

PMID:
28633695
16.

Mitigation of Discordant Rifampicin-Susceptibility Results Obtained by Xpert Mycobacterium tuberculosis/Rifampicin and Mycobacterium Growth Indicator Tube.

Gurbanova E, Mehdiyev R, Blondal K, Tahirli R, Mirzayev F, Hillemann D, Ismayilov A, Altraja A.

Microb Drug Resist. 2017 Dec;23(8):1045-1052. doi: 10.1089/mdr.2016.0149. Epub 2017 Apr 27.

PMID:
28447869
17.

Comparative accuracy of the REBA MTB MDR and Hain MTBDRplus line probe assays for the detection of multidrug-resistant tuberculosis: A multicenter, non-inferiority study.

Havumaki J, Hillemann D, Ismail N, Omar SV, Georghiou SB, Schumacher SG, Boehme C, Denkinger CM.

PLoS One. 2017 Mar 24;12(3):e0173804. doi: 10.1371/journal.pone.0173804. eCollection 2017.

18.

Feasibility and Operational Performance of Tuberculosis Detection by Loop-Mediated Isothermal Amplification Platform in Decentralized Settings: Results from a Multicenter Study.

Gray CM, Katamba A, Narang P, Giraldo J, Zamudio C, Joloba M, Narang R, Paramasivan CN, Hillemann D, Nabeta P, Amisano D, Alland D, Cobelens F, Boehme CC.

J Clin Microbiol. 2016 Aug;54(8):1984-91. doi: 10.1128/JCM.03036-15. Epub 2016 May 18.

19.

Multicenter Noninferiority Evaluation of Hain GenoType MTBDRplus Version 2 and Nipro NTM+MDRTB Line Probe Assays for Detection of Rifampin and Isoniazid Resistance.

Nathavitharana RR, Hillemann D, Schumacher SG, Schlueter B, Ismail N, Omar SV, Sikhondze W, Havumaki J, Valli E, Boehme C, Denkinger CM.

J Clin Microbiol. 2016 Jun;54(6):1624-1630. doi: 10.1128/JCM.00251-16. Epub 2016 Apr 13.

20.

External Quality Assessment for Tuberculosis Diagnosis and Drug Resistance in the European Union: A Five Year Multicentre Implementation Study.

Nikolayevskyy V, Hillemann D, Richter E, Ahmed N, van der Werf MJ, Kodmon C, Drobniewski F, Ruesch-Gerdes S; ERLTB-Net Network.

PLoS One. 2016 Apr 7;11(4):e0152926. doi: 10.1371/journal.pone.0152926. eCollection 2016.

21.

Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement.

Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, Hillemann D, Horsburgh R, Molina-Moya B, Niemann S, Tortoli E, Whitelaw A, Lange C; TBNET; RESIST-TB networks.

Int J Tuberc Lung Dis. 2016 Jan;20(1):24-42. doi: 10.5588/ijtld.15.0221. Review.

PMID:
26688526
22.

Cost-benefit analysis of Xpert MTB/RIF for tuberculosis suspects in German hospitals.

Diel R, Nienhaus A, Hillemann D, Richter E.

Eur Respir J. 2016 Feb;47(2):575-87. doi: 10.1183/13993003.01333-2015. Epub 2015 Dec 2.

23.

Mycobacterium alsense sp. nov., a scotochromogenic slow grower isolated from clinical respiratory specimens.

Tortoli E, Richter E, Borroni E, Cabibbe AM, Capitolo E, Cittaro D, Engel R, Hendricks O, Hillemann D, Kristiansen JE, Mariottini A, Schubert S, Cirillo DM.

Int J Syst Evol Microbiol. 2016 Jan;66(1):450-6. doi: 10.1099/ijsem.0.000744. Epub 2015 Nov 5.

PMID:
26545358
24.

Diagnostic Performance of the New Version (v2.0) of GenoType MTBDRsl Assay for Detection of Resistance to Fluoroquinolones and Second-Line Injectable Drugs: a Multicenter Study.

Tagliani E, Cabibbe AM, Miotto P, Borroni E, Toro JC, Mansjö M, Hoffner S, Hillemann D, Zalutskaya A, Skrahina A, Cirillo DM.

J Clin Microbiol. 2015 Sep;53(9):2961-9. doi: 10.1128/JCM.01257-15. Epub 2015 Jul 15.

25.

[Current microbiological methods in the investigation of mycobacteria].

Richter E, Andres S, Hillemann D.

Pneumologie. 2015 May;69(5):276-81. doi: 10.1055/s-0034-1391960. Epub 2015 May 13. Review. German.

26.

Genetic characterization of German Mycobacterium avium strains isolated from different hosts and specimens by multilocus sequence typing.

Kolb J, Hillemann D, Möbius P, Reetz J, Lahiri A, Lewin A, Rüsch-Gerdes S, Richter E.

Int J Med Microbiol. 2014 Nov;304(8):941-8. doi: 10.1016/j.ijmm.2014.06.001. Epub 2014 Jun 28.

PMID:
25091874
27.

Characterisation of pyrazinamide-resistant Mycobacterium tuberculosis strains isolated in Poland and Germany.

Napiórkowska A, Rüsch-Gerdes S, Hillemann D, Richter E, Augustynowicz-Kopeć E.

Int J Tuberc Lung Dis. 2014 Apr;18(4):454-60. doi: 10.5588/ijtld.13.0457.

PMID:
24670702
28.

First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries.

Hillemann D, Hoffner S, Cirillo D, Drobniewski F, Richter E, Rüsch-Gerdes S; Baltic-Nordic TB- Laboratory Network; TB PAN-NET; ECDC ERLN-TB Networks.

PLoS One. 2013 Oct 11;8(10):e76765. doi: 10.1371/journal.pone.0076765. eCollection 2013.

29.

Occurrence of rpoB mutations in isoniazid-resistant but rifampin-susceptible Mycobacterium tuberculosis isolates from Germany.

Andres S, Hillemann D, Rüsch-Gerdes S, Richter E.

Antimicrob Agents Chemother. 2014;58(1):590-2. doi: 10.1128/AAC.01752-13. Epub 2013 Oct 21.

30.

Rifampin heteroresistance in Mycobacterium tuberculosis cultures as detected by phenotypic and genotypic drug susceptibility test methods.

Folkvardsen DB, Thomsen VØ, Rigouts L, Rasmussen EM, Bang D, Bernaerts G, Werngren J, Toro JC, Hoffner S, Hillemann D, Svensson E.

J Clin Microbiol. 2013 Dec;51(12):4220-2. doi: 10.1128/JCM.01602-13. Epub 2013 Sep 25.

31.

Can molecular methods detect 1% isoniazid resistance in Mycobacterium tuberculosis?

Folkvardsen DB, Svensson E, Thomsen VØ, Rasmussen EM, Bang D, Werngren J, Hoffner S, Hillemann D, Rigouts L.

J Clin Microbiol. 2013 May;51(5):1596-9. doi: 10.1128/JCM.00472-13. Epub 2013 Feb 27.

32.

rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.

Beckert P, Hillemann D, Kohl TA, Kalinowski J, Richter E, Niemann S, Feuerriegel S.

Antimicrob Agents Chemother. 2012 May;56(5):2743-5. doi: 10.1128/AAC.06227-11. Epub 2012 Feb 27.

33.

A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay.

Blakemore R, Nabeta P, Davidow AL, Vadwai V, Tahirli R, Munsamy V, Nicol M, Jones M, Persing DH, Hillemann D, Ruesch-Gerdes S, Leisegang F, Zamudio C, Rodrigues C, Boehme CC, Perkins MD, Alland D.

Am J Respir Crit Care Med. 2011 Nov 1;184(9):1076-84. doi: 10.1164/rccm.201103-0536OC.

34.

Rapid molecular detection of extrapulmonary tuberculosis by the automated GeneXpert MTB/RIF system.

Hillemann D, Rüsch-Gerdes S, Boehme C, Richter E.

J Clin Microbiol. 2011 Apr;49(4):1202-5. doi: 10.1128/JCM.02268-10. Epub 2011 Jan 26.

35.

Rapid molecular detection of tuberculosis and rifampin resistance.

Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD.

N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847. Epub 2010 Sep 1.

36.

Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana.

Homolka S, Meyer CG, Hillemann D, Owusu-Dabo E, Adjei O, Horstmann RD, Browne EN, Chinbuah A, Osei I, Gyapong J, Kubica T, Ruesch-Gerdes S, Niemann S.

Int J Med Microbiol. 2010 Nov;300(7):489-95. doi: 10.1016/j.ijmm.2010.04.019. Epub 2010 Jun 9.

PMID:
20538518
37.

Drug-susceptibility testing in TB: current status and future prospects.

Richter E, Rüsch-Gerdes S, Hillemann D.

Expert Rev Respir Med. 2009 Oct;3(5):497-510. doi: 10.1586/ers.09.45.

PMID:
20477339
38.

Airborne Mycobacterium avium infection in a group of red-shanked douc langurs (Pygathrix nemaeus nemaeus).

Plesker R, Teschner K, Behlert O, Prenger-Berninghoff E, Hillemann D.

J Med Primatol. 2010 Apr;39(2):129-35. doi: 10.1111/j.1600-0684.2010.00406.x. Epub 2010 Feb 19.

PMID:
20202077
39.

Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens.

Hillemann D, Rüsch-Gerdes S, Richter E.

J Clin Microbiol. 2009 Jun;47(6):1767-72. doi: 10.1128/JCM.00081-09. Epub 2009 Apr 22.

40.

[Modern laboratory diagnostics for mycobacteria].

Rüsch-Gerdes S, Hillemann D.

Pneumologie. 2008 Sep;62(9):533-40. doi: 10.1055/s-2008-1038242. Epub 2008 Sep 3. Review. German.

PMID:
18770479
41.

[Antibiotic drug-resistant tuberculosis].

Greinert U, Hillemann D, Lange C, Richter E.

Med Klin (Munich). 2007 Dec 15;102(12):957-66. Review. German.

PMID:
18075716
42.

In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants.

Hillemann D, Rüsch-Gerdes S, Richter E.

Antimicrob Agents Chemother. 2008 Feb;52(2):800-1. Epub 2007 Dec 10. No abstract available.

43.

Mycobacterium alsiense, a novel, slowly growing species isolated from two patients with pulmonary disease.

Richter E, Tortoli E, Fischer A, Hendricks O, Engel R, Hillemann D, Schubert S, Kristiansen JE.

J Clin Microbiol. 2007 Nov;45(11):3837-9. Epub 2007 Sep 5.

44.
45.

First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.

Richter E, Rüsch-Gerdes S, Hillemann D.

Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6. Epub 2007 Jan 22.

46.

Evaluation of molecular-Beacon, TaqMan, and fluorescence resonance energy transfer probes for detection of antibiotic resistance-conferring single nucleotide polymorphisms in mixed Mycobacterium tuberculosis DNA extracts.

Yesilkaya H, Meacci F, Niemann S, Hillemann D, Rüsch-Gerdes S; LONG DRUG Study Group, Barer MR, Andrew PW, Oggioni MR.

J Clin Microbiol. 2006 Oct;44(10):3826-9.

47.
48.

Application of the Genotype MTBDR assay directly on sputum specimens.

Hillemann D, Rüsch-Gerdes S, Richter E.

Int J Tuberc Lung Dis. 2006 Sep;10(9):1057-9.

PMID:
16964801
49.

MaxiK blockade selectively inhibits the lipopolysaccharide-induced I kappa B-alpha /NF-kappa B signaling pathway in macrophages.

Papavlassopoulos M, Stamme C, Thon L, Adam D, Hillemann D, Seydel U, Schromm AB.

J Immunol. 2006 Sep 15;177(6):4086-93.

50.

Evaluation of the GenoType Mycobacterium Assay for identification of mycobacterial species from cultures.

Richter E, Rüsch-Gerdes S, Hillemann D.

J Clin Microbiol. 2006 May;44(5):1769-75.

Supplemental Content

Loading ...
Support Center